170 results on '"H.L.A. Janssen"'
Search Results
2. Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase
Catalog
Books, media, physical & digital resources
3. Ziekten van lever en galwegen
4. Polymorphisms ofHLA-DPare associated with response to peginterferon in Caucasian patients with chronic hepatitis B
5. Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity
6. Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis
7. Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis– the Global PBC Study Group
8. Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study
9. Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis
10. DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment
11. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122
12. HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy
13. Genetic polymorphisms in innate immunity receptors do not predict the risk of bacterial and fungal infections and acute rejection after liver transplantation
14. Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression
15. A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
16. Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis
17. On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB
18. The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time
19. Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study
20. Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)
21. Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis
22. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C
23. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
24. A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis
25. Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B
26. Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements
27. Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC)
28. Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study
29. Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada
30. The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy
31. Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response
32. Review article: the management of non-cirrhotic non-malignant portal vein thrombosis and concurrent portal hypertension in adults
33. In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection
34. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon alpha-2b therapy
35. Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in 3529 Patients with Primary Biliary Cholangitis
36. Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study
37. A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results
38. Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum Levels of Lysyl Oxidase-Like-2 (Loxl2)
39. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection
40. Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study
41. Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years
42. A randomized controlled trial of US vs US + biomarkers for the diagnosis of hepatocellular carcinoma: an interim report
43. Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions?
44. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
45. Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
46. P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC)
47. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection
48. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding
49. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
50. Polymorphisms of HLA-DPB1 are Associated with Long-Term Clinical Outcome in a Diverse Cohort of Chronic Hepatitis B Patients
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.